Major histocompatibility complex class I molecules presenting Human papillomavirus type 16 E6 shuffled protein-derived peptides (MHC-I/HPV16-E6SH)

MHC class I molecules presenting HPV16 E6SH-derived peptides are cell-surface complexes consisting of a Major Histocompatibility Complex (MHC) class I protein and a peptide fragment derived from a shuffled version of the Human Papillomavirus type 16 (HPV16) E6 oncoprotein. The E6SH (shuffled E6) protein is a genetically engineered variant designed to eliminate the oncogenic activity of the wild-type E6 protein, specifically its ability to induce p53 degradation, while maintaining the full sequence of potential T-cell epitopes for immune recognition (Source 1.3.2, 1.3.4). These complexes are primarily found on the surface of HPV16-infected or transformed cells and serve as the primary recognition target for CD8+ cytotoxic T lymphocytes (CTLs) (Source 1.1.1, 1.2.3). In therapeutic contexts, this target is exploited by DNA vaccines, such as sig-HELP-E6SH-KDEL, and adoptive T-cell therapies to stimulate a robust immune response against HPV-associated malignancies, including cervical, vulvar, and head and neck cancers (Source 1.3.1, 1.3.5). By focusing on the peptide-MHC complex, these therapies aim to selectively eliminate cancerous cells that constitutively express the viral oncoprotein while minimizing damage to healthy tissues. The use of a shuffled protein sequence ensures that the vaccine itself does not promote tumor growth while still providing the necessary antigens for effective immune surveillance (Source 1.3.4).

Other names

HPV16 E6 shuffled peptide-MHC complexMHC-I/E6SHHLA-A*02:01/HPV16 E6SH complexpMHC HPV16 E6SHHPV16 E6SH-derived peptide-HLA complex

Antigen presentation to CD8+ cytotoxic T lymphocytes leading to the targeted lysis of HPV16-infected or transformed cells